M Grunnet1, I J Christensen2, U Lassen3, L H Jensen4, M Lydolph5, I K Lund6, T Thurison7, G Høyer-Hansen8, M Mau-Sørensen9. 1. Dept. of Oncology, Rigshospitalet, DK-2100 Copenhagen Ø, Denmark. Electronic address: mie.grunnet.knudsen@regionh.dk. 2. The Finsen Laboratory, Rigshospitalet & Biotech Research and Innovation Centre, University of Copenhagen, DK-2200 Copenhagen N, Denmark. Electronic address: ib.jarle.christensen@regionh.dk. 3. Dept. of Oncology, Rigshospitalet, DK-2100 Copenhagen Ø, Denmark. Electronic address: ulrik.lassen@regionh.dk. 4. Dept. Of Oncology, Lillebælt Hospital Vejle, DK-7100 Vejle, Denmark. Electronic address: lars.henrik.jensen@slb.regionsyddanmark.dk. 5. Dept. Of Clinical biochemistry and Immunology, National Institute for Health Data and Disease Control, DK-2300 Copenhagen S, Denmark. Electronic address: mlp@ssi.dk. 6. The Finsen Laboratory, Rigshospitalet & Biotech Research and Innovation Centre, University of Copenhagen, DK-2200 Copenhagen N, Denmark. Electronic address: ikl@finsenlab.dk. 7. The Finsen Laboratory, Rigshospitalet & Biotech Research and Innovation Centre, University of Copenhagen, DK-2200 Copenhagen N, Denmark. Electronic address: tinets@finsenlab.dk. 8. The Finsen Laboratory, Rigshospitalet & Biotech Research and Innovation Centre, University of Copenhagen, DK-2200 Copenhagen N, Denmark. Electronic address: gunilla@finsenlab.dk. 9. Dept. of Oncology, Rigshospitalet, DK-2100 Copenhagen Ø, Denmark. Electronic address: morten.mau.soerensen@regionh.dk.
Abstract
BACKGROUND: High levels of intact and cleaved forms of the urokinase-type plasminogen activator receptor (uPAR) in both tissue and blood are associated with poor survival in several cancer diseases. The prognostic significance of uPAR in cholangiocarcinoma is unknown. The aims of this study were to determine if pre-treatment serum levels of uPAR forms and a decrease in levels during chemotherapy are predictive of survival in patients with inoperable cholangiocarcinoma. DESIGN AND METHODS: Patients with inoperable cholangiocarcinoma were consecutively included in the training set (n=108). A test set included patients from a different hospital using similar treatment guidelines (n=60). Serum levels of the different uPAR forms were determined using time-resolved fluorescence immunoassays (TR-FIA). The Cox proportional hazards model was used for the uni- and multivariate survival analyses. RESULTS: Baseline level of uPAR(I-III)+uPAR(II-III) was an independent predictor of survival (HR=2.08, 95% CI:1.46-2.97, p<0.0001). Applying the linear predictor from the training set to the test set, it was validated that uPAR(I-III)+uPAR(II-III) predicted overall survival (p=0.049). A high level of uPAR(I-III)+uPAR(II-III) after 2cycles of chemotherapy was associated with poor survival (HR=1.79, 95% CI:1.08-2.97, p=0.023, n=57). This predictor, however, was not significant in the test set (p=0.21, 26 events in 27 patients). CONCLUSION: The baseline level of uPAR(I-III)+uPAR(II-III) is a predictor of survival in inoperable cholangiocarcinoma patients.
BACKGROUND: High levels of intact and cleaved forms of the urokinase-type plasminogen activator receptor (uPAR) in both tissue and blood are associated with poor survival in several cancer diseases. The prognostic significance of uPAR in cholangiocarcinoma is unknown. The aims of this study were to determine if pre-treatment serum levels of uPAR forms and a decrease in levels during chemotherapy are predictive of survival in patients with inoperable cholangiocarcinoma. DESIGN AND METHODS: Patients with inoperable cholangiocarcinoma were consecutively included in the training set (n=108). A test set included patients from a different hospital using similar treatment guidelines (n=60). Serum levels of the different uPAR forms were determined using time-resolved fluorescence immunoassays (TR-FIA). The Cox proportional hazards model was used for the uni- and multivariate survival analyses. RESULTS: Baseline level of uPAR(I-III)+uPAR(II-III) was an independent predictor of survival (HR=2.08, 95% CI:1.46-2.97, p<0.0001). Applying the linear predictor from the training set to the test set, it was validated that uPAR(I-III)+uPAR(II-III) predicted overall survival (p=0.049). A high level of uPAR(I-III)+uPAR(II-III) after 2cycles of chemotherapy was associated with poor survival (HR=1.79, 95% CI:1.08-2.97, p=0.023, n=57). This predictor, however, was not significant in the test set (p=0.21, 26 events in 27 patients). CONCLUSION: The baseline level of uPAR(I-III)+uPAR(II-III) is a predictor of survival in inoperable cholangiocarcinomapatients.
Authors: Line Hammer Dohn; Helle Pappot; Benedikte Richter Iversen; Martin Illemann; Gunilla Høyer-Hansen; Ib Jarle Christensen; Peter Thind; Lisbeth Salling; Hans von der Maase; Ole Didrik Laerum Journal: PLoS One Date: 2015-08-20 Impact factor: 3.240
Authors: Sandra Pavicevic; Sophie Reichelt; Deniz Uluk; Isabella Lurje; Cornelius Engelmann; Dominik P Modest; Uwe Pelzer; Felix Krenzien; Nathanael Raschzok; Christian Benzing; Igor M Sauer; Sebastian Stintzing; Frank Tacke; Wenzel Schöning; Moritz Schmelzle; Johann Pratschke; Georg Lurje Journal: Cancers (Basel) Date: 2022-02-17 Impact factor: 6.639